COPENHAGEN, June 28 Danish drugmaker Novo
Nordisk (NOVOb.CO) is applying for U.S. approval for use of its
diabetes drug Victoza in combination with long-acting insulins.
Spokesman Mike Rulis declined to say on Tuesday how long
Novo Nordisk expected the review process to take.
Victoza has been approved by a number of different
regulatory agencies as a once-daily injection for the treatment
of adults with type 2 diabetes. It is not an insulin, but rather
a human GLP-1 (Glucagon-Like Peptide-1) analogue that stimulates
the body's own release of insulin.
Long-acting insulins on the market include Novo Nordisk's
own Levemir and French rival Sanofi-Aventis's Lantus.
"The study that forms the basis for (this application) was a
study with our own long-acting insulin, Levemir," Rulis said.
Novo Nordisk presented new data on June 25 at the American
Diabetes Association conference in San Diego, California, that
showed Victoza in combination with Levemir helped patients reach
and maintain blood sugar targets with low frequency of
hypoglycaemia and to maintain weight loss.
(Reporting by John Acher; Editing by Dan Lalor)